TELA Bio, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by TELA Bio, Inc. on June 1, 2023. The record date for the meeting was April 5, 2023, with 19,227,777 outstanding shares of common stock. The meeting was conducted virtually.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The primary events are the election of directors and the ratification of the independent auditor.
Guidance, Outlook, and Voting Results
The filing details the final voting results for two proposals:
- Proposal 1: Election of Class I Directors
- Lisa Colleran: Elected with 14,316,642 votes For, 1,055,675 Withheld, and 1,821,457 Broker Non-Votes.
- Doug Evans: Elected with 13,535,182 votes For, 1,837,135 Withheld, and 1,821,457 Broker Non-Votes.
- Both directors will serve until the 2026 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Public Accountants
- KPMG LLP was ratified as the independent auditor for the 2023 fiscal year.
- Votes For: 17,188,505
- Votes Against: 3,312
- Abstentions: 1,957
- Broker Non-Votes: 0
The filing contains no specific management commentary on future guidance, risks, or contingencies beyond the standard disclosure of the voting outcomes.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 17, 2023, for detailed biographies of the newly elected directors and the rationale for the auditor selection.
- Confirm the total number of shares outstanding (19,227,777) against the most recent quarterly or annual report to ensure no subsequent capital changes.
- Review the Company's latest 10-K or 10-Q for financial performance metrics, as this 8-K does not contain financial data.